STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation.
Read more at globenewswire.comGreenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Provided By GlobeNewswire – Last update: